Trial Profile
A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Zatolmilast (Primary)
- Indications Fragile X syndrome; Mental retardation
- Focus Adverse reactions
- Sponsors Tetra Therapeutics
- 02 Nov 2020 Status changed from active, no longer recruiting to completed as per the Tetra Therapeutics Media Release.
- 02 Nov 2020 Results published in the Tetra Therapeutics Media Release.
- 02 Nov 2020 Results published in Shionogi Media Release